Myomo® Announces Participation in Beijing Trade Show
May 23 2019 - 8:05AM
Business Wire
Myomo to Attend with Ryzur Medical to Assess
Chinese Market Opportunity
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a
wearable medical robotics company that offers increased
functionality for those suffering from neurological disorders and
upper limb paralysis, announces its participation in the China
International Fair for Trade in Services, to be held in Beijing
from May 28-31, 2019. Myomo will participate in this event together
with Beijing Ryzur Medical Investment Co., Ltd. (Ryzur Medical), a
growing medical device manufacturer based in Beijing.
Paul R. Gudonis, Chairman and CEO of Myomo, said, “We are
already positioned to provide our powered arm braces to individuals
in North America and selected markets in Europe, and Asia
represents another major region with a large population of patients
with arm and hand paralysis. By attending this event with Ryzur
Medical, we are beginning the process of exploring the potential to
address this important future market for Myomo. We are eager to
learn more about the opportunity in China and to continue toward
our goal of becoming the worldwide standard of care for upper
extremity paralysis.”
About Myomo
Myomo, Inc. is a wearable medical robotics company that offers
expanded mobility for those suffering from neurological disorders
and upper limb paralysis. Myomo develops and markets the MyoPro
product line. MyoPro is a powered upper limb orthosis designed to
support the arm and restore function to the weakened or paralyzed
arms of patients suffering from CVA stroke, brachial plexus injury,
traumatic brain or spinal cord injury, ALS or other neuromuscular
disease or injury. It is currently the only marketed device that,
sensing a patient’s own EMG signals through non-invasive sensors on
the arm, can restore an individual’s ability to perform activities
of daily living, including feeding themselves, carrying objects and
doing household tasks. Many are able to return to work, live
independently and reduce their cost of care. Myomo is headquartered
in Cambridge, Massachusetts, with sales and clinical professionals
across the U.S. and representatives internationally. For more
information, please visit www.myomo.com.
About Beijing Ryzur Medical Investment Co., Ltd.
Ryzur Medical is a comprehensive provider that integrates
medical technology and services, medical equipment, medical
services, and medical investment.
At present, the company is divided into two business units:
high-end rehabilitation medical technology and equipment supply and
professional medical services. In terms of medical services, Ryzur
Medical currently directly manages five hospitals and provide
rehabilitation medical technical services and medical services.
Ryzur Medical also provides more than 200 models of
rehabilitation medical equipment in seven product lines, including
orthopedic rehabilitation, neurological rehabilitation,
rehabilitation assessment and physical therapy. The company owns
the world-leading Non-Surgical Spinal Decompression System (SDS)
technology. Ryzur Medical has strict requirements on production
process and quality. All medical equipment undergoes strict
standard procedure testing and performance monitoring before it
leaves the factory. Ryzur Medical pursues zero-defect quality and
zero-complaint service. For more information, please visit
www.ryzur.com.cn.
Forward Looking StatementsThis press release contains
forward-looking statements regarding the Company's future business
expectations which are subject to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, our
potential future business in Asia. These forward-looking statements
are only predictions and may differ materially from actual results
due to a variety of factors. Our actual results could differ
materially from those anticipated in these forward looking
statements for many reasons, including, without limitation, risks
related to regulatory approval and market acceptance of our
products, our ability to secure and maintain reimbursement for our
products, our ability to obtain additional funding to sustain and
grow our business, and the other risk factors contained in our
filings made with the Securities and Exchange Commission. More
information about factors that potentially could affect Myomo's
business and financial results is included in Myomo's filings with
the Securities and Exchange Commission. The Company cautions
readers not to place undue reliance on any such forward-looking
statements, which speak only as of the date made. The Company
disclaims any obligation subsequently to revise any forward-looking
statements to reflect events or circumstances after the date of
such statements or to reflect the occurrence of anticipated or
unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190523005058/en/
Investor Relations:Vivian CervantesPCG
Advisory646-863-6274vivian@pcgadvisory.com
Public Relations:Sarah KarrMatter
Communications978-518-4817myomo@matternow.com
Myomo (AMEX:MYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From Apr 2023 to Apr 2024